Try it
Pharmacology · Antidepressants: esketamine
Sample itemIntranasal esketamine is approved for treatment-resistant depression. What is its primary pharmacological target?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
B. NMDA glutamate receptor antagonism
Esketamine is the S-enantiomer of ketamine and blocks NMDA receptors, producing rapid antidepressant action through glutamatergic signalling. It is given under supervision because of dissociation, blood pressure rise and abuse potential.
Option by option
A. 5-HT reuptake transporter
Reuptake inhibition describes SSRIs.
B. NMDA glutamate receptor antagonism (correct)
Correct. NMDA antagonism underlies its action.
C. GABA-A receptor positive modulation
GABA-A modulation describes benzodiazepines.
D. MAO-A enzyme
MAO inhibition describes phenelzine and moclobemide.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Pharmacology questions
- Emergency drugsA patient develops stridor, wheeze and hypotension minutes after an injection. What is t…
- AntiepilepticsWhat is the preferred first-line drug for a patient in generalised convulsive status epi…
- AntimicrobialsWhich drug can cause a disulfiram-like reaction when taken with alcohol?
- AntiepilepticsWhich drug is preferred for uncomplicated childhood absence seizures?